Carriage of Streptococcus pneumoniae 3 Years after Start of Vaccination Program, the Netherlands

To evaluate the effectiveness of the 7-valent pneumococcal conjugate vaccine (PCV7) program, we conducted a cross-sectional observational study on nasopharyngeal carriage of Streptococcus pneumoniae 3 years after implementation of the program in the Netherlands. We compared pneumococcal serotypes in 329 prebooster 11-month-old children, 330 fully vaccinated 24-month-old children, and 324 parents with age-matched pre-PCV7 (unvaccinated) controls (ages 12 and 24 months, n = 319 and n = 321, respectively) and 296 of their parents. PCV7 serotype prevalences before and after PCV7 implementation, re... Mehr ...

Verfasser: Judith Spijkerman
Elske J.M. van Gils
Reinier H. Veenhoven
Eelko Hak
F. Yzerman
Arie van der Ende
Alienke J. Wijmenga-Monsuur
Germie P.J.M. van den Dobbelsteen
Elisabeth A.M. Sanders
Dokumenttyp: Artikel
Erscheinungsdatum: 2011
Reihe/Periodikum: Emerging Infectious Diseases, Vol 17, Iss 4, Pp 584-591 (2011)
Verlag/Hrsg.: Centers for Disease Control and Prevention
Schlagwörter: Streptococcus pneumoniae / nasopharyngeal colonization / heptavalent pneumococcal conjugate vaccine / infectious disease transmission / herd immunity / parents / Medicine / R / Infectious and parasitic diseases / RC109-216
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26802290
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.3201/eid1704.101115

To evaluate the effectiveness of the 7-valent pneumococcal conjugate vaccine (PCV7) program, we conducted a cross-sectional observational study on nasopharyngeal carriage of Streptococcus pneumoniae 3 years after implementation of the program in the Netherlands. We compared pneumococcal serotypes in 329 prebooster 11-month-old children, 330 fully vaccinated 24-month-old children, and 324 parents with age-matched pre-PCV7 (unvaccinated) controls (ages 12 and 24 months, n = 319 and n = 321, respectively) and 296 of their parents. PCV7 serotype prevalences before and after PCV7 implementation, respectively, were 38% and 8% among 11-month-old children, 36% and 4% among 24-month-old children, and 8% and 1% among parents. Non-PCV7 serotype prevalences were 29% and 39% among 11-month-old children, 30% and 45% among 24-month-old children, and 8% and 15% among parents, respectively; serotypes 11A and 19A were most frequently isolated. PCV7 serotypes were largely replaced by non-PCV7 serotypes. Disappearance of PCV7 serotypes in parents suggests strong transmission reduction through vaccination.